PE20090727A1 - DERIVADOS DE AMIDA COMO INHIBIDORES DE NaV1.7 - Google Patents

DERIVADOS DE AMIDA COMO INHIBIDORES DE NaV1.7

Info

Publication number
PE20090727A1
PE20090727A1 PE2008000697A PE2008000697A PE20090727A1 PE 20090727 A1 PE20090727 A1 PE 20090727A1 PE 2008000697 A PE2008000697 A PE 2008000697A PE 2008000697 A PE2008000697 A PE 2008000697A PE 20090727 A1 PE20090727 A1 PE 20090727A1
Authority
PE
Peru
Prior art keywords
pyridin
chromen
benzamide
dihydro
amida
Prior art date
Application number
PE2008000697A
Other languages
English (en)
Spanish (es)
Inventor
Yevgeni Besidski
Inger Kers
Martin Nylof
Lars Sandberg
Karin Skogholm
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39876087&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090727(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20090727A1 publication Critical patent/PE20090727A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PE2008000697A 2007-04-23 2008-04-23 DERIVADOS DE AMIDA COMO INHIBIDORES DE NaV1.7 PE20090727A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91331207P 2007-04-23 2007-04-23

Publications (1)

Publication Number Publication Date
PE20090727A1 true PE20090727A1 (es) 2009-07-23

Family

ID=39876087

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000697A PE20090727A1 (es) 2007-04-23 2008-04-23 DERIVADOS DE AMIDA COMO INHIBIDORES DE NaV1.7

Country Status (23)

Country Link
US (2) US8143408B2 (cg-RX-API-DMAC7.html)
EP (1) EP2158198B1 (cg-RX-API-DMAC7.html)
JP (1) JP2010525056A (cg-RX-API-DMAC7.html)
KR (1) KR20100015827A (cg-RX-API-DMAC7.html)
CN (1) CN101687860B (cg-RX-API-DMAC7.html)
AR (1) AR066266A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008241610B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0810354A2 (cg-RX-API-DMAC7.html)
CA (1) CA2685141A1 (cg-RX-API-DMAC7.html)
CL (1) CL2008001170A1 (cg-RX-API-DMAC7.html)
CO (1) CO6251361A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP099706A (cg-RX-API-DMAC7.html)
IL (1) IL201309A0 (cg-RX-API-DMAC7.html)
MX (1) MX2009011364A (cg-RX-API-DMAC7.html)
MY (1) MY146662A (cg-RX-API-DMAC7.html)
NZ (1) NZ581353A (cg-RX-API-DMAC7.html)
PE (1) PE20090727A1 (cg-RX-API-DMAC7.html)
RU (1) RU2460730C2 (cg-RX-API-DMAC7.html)
SA (1) SA08290245B1 (cg-RX-API-DMAC7.html)
TW (1) TW200848037A (cg-RX-API-DMAC7.html)
UY (1) UY31046A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008130320A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200907137B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA08290245B1 (ar) * 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم
AR074760A1 (es) * 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
EP2942346B1 (en) 2009-02-17 2020-05-06 Syntrix Biosystems, Inc. Pyridinecarboxamides as cxcr2 modulators
CN106117213B (zh) * 2009-10-26 2022-03-18 西格诺药品有限公司 杂芳基化合物及其合成和纯化方法
UA103272C2 (uk) 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
JPWO2011093501A1 (ja) 2010-02-01 2013-06-06 日本ケミファ株式会社 Ｇｐｒ１１９作動薬
AU2011293612B2 (en) * 2010-08-23 2015-11-26 Syntrix Biosystems Inc. Aminopyridine- and aminopyrimidinecarboxamides as CXCR2 modulators
WO2012039657A1 (en) * 2010-09-22 2012-03-29 Astrazeneca Ab Novel chromane compound for the treatment of pain disorders
CN102408385B (zh) * 2011-06-20 2014-06-18 雅本化学股份有限公司 一种2-取代-2h-1,2,3-三氮唑衍生物的制备方法
CN102408386B (zh) * 2011-07-27 2014-05-07 雅本化学股份有限公司 2,4-二取代-2h-1,2,3-三氮唑衍生物的制备方法
CN102603659B (zh) * 2012-03-01 2014-03-26 雅本化学股份有限公司 1-取代-4-溴-1h-1,2,3-三氮唑-5-羧酸及其制备方法
AU2014212426B8 (en) * 2013-01-31 2018-05-10 Vertex Pharmaceuticals Incorporated Quinoline and Quinoxaline Amides as Modulators of Sodium Channels
US10561676B2 (en) 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US8969365B2 (en) 2013-08-02 2015-03-03 Syntrix Biosystems, Inc. Thiopyrimidinecarboxamides as CXCR1/2 modulators
KR20160118345A (ko) * 2014-02-06 2016-10-11 애브비 인코포레이티드 6-헤테로아릴옥시- 및 6-아릴옥시-퀴놀린-2-카복사미드 및 이의 용도
KR102412146B1 (ko) 2015-02-11 2022-06-22 주식회사 아이엔테라퓨틱스 소디움 채널 차단제
US10227338B2 (en) 2015-11-13 2019-03-12 Daewoong Pharmaceutical Co., Ltd. Substituted benzenesulfonamides as sodium channel blockers
CN105541774B (zh) * 2016-01-13 2018-06-15 华中师范大学 3,4-二氢香豆素类化合物及其制备方法和用途
PL3615527T3 (pl) * 2017-06-30 2024-07-01 Elanco Animal Health Gmbh Nowe pochodne azachinoliny
MX2020007532A (es) 2018-01-19 2020-09-09 Cytokinetics Inc Inhibidores de sarcomero cardiaco.
AU2019232437A1 (en) 2018-03-07 2020-10-08 Bayer Aktiengesellschaft Identification and use of ERK5 inhibitors
US11964967B2 (en) 2018-06-26 2024-04-23 Cytokinetics, Inc. Cardiac sarcomere inhibitors
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
KR102812440B1 (ko) 2018-09-10 2025-05-26 가껭세이야꾸가부시기가이샤 신규한 헤테로방향족 아미드 유도체 및 이를 함유하는 약제
US20220227729A1 (en) 2019-05-21 2022-07-21 Bayer Aktiengesellschaft Identification and use of kras inhibitors
JP2024508526A (ja) 2021-03-04 2024-02-27 サイトキネティックス， インコーポレイテッド 心筋サルコメア阻害剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8904361D0 (sv) * 1989-12-22 1989-12-22 Astra Ab New chroman and thiochroman derivatives
WO1994012493A1 (en) * 1992-11-25 1994-06-09 Sandoz, Ltd. 2,2-dialkyl- and 2,2-dialkyl-3,4-dihydro-3-hydroxy-2h-1-benzopyr ans, their use as pharmaceuticals
JPH0827153A (ja) * 1994-07-12 1996-01-30 Nippon Kayaku Co Ltd アザクロマン誘導体及びその用途
SE9601110D0 (sv) 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
GB9713804D0 (en) * 1997-06-30 1997-09-03 Novo Nordisk As Particulate polymeric materials and their use
JPH1135569A (ja) 1997-07-22 1999-02-09 Meiji Milk Prod Co Ltd ポリフェノール化合物及びこれを含有する医薬
SE9702799D0 (sv) 1997-07-25 1997-07-25 Astra Ab New compounds
SE9703378D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
SE9703377D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
CA2539227A1 (en) * 2003-08-08 2005-02-17 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
US7615563B2 (en) 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
WO2006119451A1 (en) * 2005-05-04 2006-11-09 Vertex Pharmaceuticals Incorporated Pyrimidines and pyrazines useful as modulators of ion channels
US20090291983A1 (en) * 2006-07-12 2009-11-26 Astrazeneca Ab 3-Oxoisoindoline-1-Carboxamide Derivatives as Analgesic Agents
SA08290245B1 (ar) * 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم

Also Published As

Publication number Publication date
AR066266A1 (es) 2009-08-05
CN101687860A (zh) 2010-03-31
EP2158198B1 (en) 2013-03-20
RU2009138137A (ru) 2011-05-27
CO6251361A2 (es) 2011-02-21
JP2010525056A (ja) 2010-07-22
CN101687860B (zh) 2012-07-04
EP2158198A2 (en) 2010-03-03
UY31046A1 (es) 2008-11-28
AU2008241610B2 (en) 2011-08-18
AU2008241610A1 (en) 2008-10-30
CL2008001170A1 (es) 2009-05-22
EP2158198A4 (en) 2012-01-04
KR20100015827A (ko) 2010-02-12
US8143408B2 (en) 2012-03-27
BRPI0810354A2 (pt) 2014-10-21
SA08290245B1 (ar) 2012-02-12
TW200848037A (en) 2008-12-16
ZA200907137B (en) 2010-07-28
WO2008130320A2 (en) 2008-10-30
MY146662A (en) 2012-09-14
NZ581353A (en) 2012-02-24
WO2008130320A3 (en) 2008-12-18
US20100137322A1 (en) 2010-06-03
US20120238579A1 (en) 2012-09-20
RU2460730C2 (ru) 2012-09-10
ECSP099706A (es) 2009-11-30
CA2685141A1 (en) 2008-10-30
IL201309A0 (en) 2010-05-31
MX2009011364A (es) 2009-11-05

Similar Documents

Publication Publication Date Title
PE20090727A1 (es) DERIVADOS DE AMIDA COMO INHIBIDORES DE NaV1.7
PE20090606A1 (es) Nuevos inhibidores de catepsina c y uso
PE20110367A1 (es) DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2
PE20211700A1 (es) Compuesto heterociclico y su uso
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
PE20090641A1 (es) Amidas heterociclicas
PE20090772A1 (es) Derivados de bencimidazol
PE20142185A1 (es) Pirrolidina-2-carboxamidas sustituidas
PE20080951A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
BRPI0410727A (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0409227B8 (pt) "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)"
PE20080906A1 (es) Derivados heteroarilo como inhibidores de citocina
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
EA202092168A1 (ru) Применение фавипиравира в лечении коронавирусной инфекции
CL2009000394A1 (es) Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer.
PE20040647A1 (es) Inhibidores de cinasas de tirosina
EA201070442A1 (ru) НОВЫЕ ИНГИБИТОРЫ sEH И ИХ ПРИМЕНЕНИЕ
PE20040993A1 (es) Derivados de taxano y de isotiazol referidos a enfermedades hiperproliferativas
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
PE20090649A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
PE20140966A1 (es) Quinazolincarboxamida azetidinas
PE20080702A1 (es) PROLINAMIDAS SUSTITUIDAS COMO INHIBIDORES DEL FACTOR Xa
ATE384058T1 (de) Thiazolderivate
PE20091400A1 (es) Derivados de n-(2-amino-fenil)-amida como inhibidores de hdac
PE20231746A1 (es) Compuestos de union a cereblon, composiciones de estos y metodos de tratamiento con estos

Legal Events

Date Code Title Description
FC Refusal